BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 31748121)

  • 1. Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology
    Breccia M; Carver JR; Szmit S; Jurczak W; Salvatorelli E; Minotti G
    Semin Oncol; 2019 Dec; 46(6):403-407. PubMed ID: 31748121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology.
    Yeh ETH; Ewer MS; Moslehi J; Dlugosz-Danecka M; Banchs J; Chang HM; Minotti G
    Semin Oncol; 2019 Dec; 46(6):397-402. PubMed ID: 31753424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardio-oncological management of patients.
    Cardinale DM; Barac A; Torbicki A; Khandheria BK; Lenihan D; Minotti G
    Semin Oncol; 2019 Dec; 46(6):408-413. PubMed ID: 31784042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
    Sethi TK; Basdag B; Bhatia N; Moslehi J; Reddy NM
    Curr Hematol Malig Rep; 2017 Jun; 12(3):257-267. PubMed ID: 28233150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardio-oncology in clinical studies and real life.
    Dent SF; Suter TM; López-Fernández T; Opolski G; Menna P; Minotti G
    Semin Oncol; 2019 Dec; 46(6):421-425. PubMed ID: 31767270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies to Prevent Cardiotoxicity.
    Graffagnino J; Kondapalli L; Arora G; Hawi R; Lenneman CG
    Curr Treat Options Oncol; 2020 Apr; 21(4):32. PubMed ID: 32270293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).
    Bringhen S; Milan A; Ferri C; Wäsch R; Gay F; Larocca A; Salvini M; Terpos E; Goldschmidt H; Cavo M; Petrucci MT; Ludwig H; Auner HW; Caers J; Gramatzki M; Boccadoro M; Einsele H; Sonneveld P; Engelhardt M;
    Haematologica; 2018 Sep; 103(9):1422-1432. PubMed ID: 30049825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Helping the cardio-oncologist: from real life to guidelines.
    Armenian SH; Jurczak W; Carver JR; Gennari A; Minotti G; Ewer MS
    Semin Oncol; 2019 Dec; 46(6):433-436. PubMed ID: 31784041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cardiovascular complications of cancers and anti-cancer therapy].
    Vyskočil J; Petráková K; Jelínek P; Furdek M
    Vnitr Lek; 2017; 63(3):200-209. PubMed ID: 28379023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014).
    Ewer M; Gianni L; Pane F; Sandri MT; Steiner RK; Wojnowski L; Yeh ET; Carver JR; Lipshultz SE; Minotti G; Armstrong GT; Cardinale D; Colan SD; Darby SC; Force TL; Kremer LC; Lenihan DJ; Sallan SE; Sawyer DB; Suter TM; Swain SM; van Leeuwen FE
    Ecancermedicalscience; 2014; 8():433. PubMed ID: 24932213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular events in cancer survivors.
    Howard E; Steingart RM; Armstrong GT; Lyon AR; Armenian SH; Teresa Voso M; Cicconi L; Coco FL; Minotti G
    Semin Oncol; 2019 Dec; 46(6):426-432. PubMed ID: 31791551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management.
    Sundararajan S; Kumar A; Poongkunran M; Kannan A; Vogelzang NJ
    Future Oncol; 2016; 12(8):1067-80. PubMed ID: 26901457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms.
    Pantazi D; Tselepis AD
    Thromb Res; 2022 May; 213 Suppl 1():S95-S102. PubMed ID: 36210569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.
    Albini A; Pennesi G; Donatelli F; Cammarota R; De Flora S; Noonan DM
    J Natl Cancer Inst; 2010 Jan; 102(1):14-25. PubMed ID: 20007921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comprehensive Review of Cancer Drug-Induced Cardiotoxicity in Blood Cancer Patients: Current Perspectives and Therapeutic Strategies.
    Costanzo V; Ratre YK; Andretta E; Acharya R; Bhaskar LVKS; Verma HK
    Curr Treat Options Oncol; 2024 Apr; 25(4):465-495. PubMed ID: 38372853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac Complications in the Adult Bone Marrow Transplant Patient.
    Tuzovic M; Mead M; Young PA; Schiller G; Yang EH
    Curr Oncol Rep; 2019 Mar; 21(3):28. PubMed ID: 30826891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antineoplastic drugs inducing cardiac and vascular toxicity - An update.
    Barachini S; Ghelardoni S; Varga ZV; Mehanna RA; Montt-Guevara MM; Ferdinandy P; Madonna R
    Vascul Pharmacol; 2023 Dec; 153():107223. PubMed ID: 37678516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy-induced cardiomyopathy.
    Higgins AY; O'Halloran TD; Chang JD
    Heart Fail Rev; 2015 Nov; 20(6):721-30. PubMed ID: 26338137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy and Cardiotoxicity in Hematologic Malignancies.
    Stellitano A; Fedele R; Barilla S; Iaria A; Rao CM; Martino M
    Curr Cancer Drug Targets; 2017; 17(4):311-324. PubMed ID: 27903214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The concomitant management of cancer therapy and cardiac therapy.
    Salvatorelli E; Menna P; Cantalupo E; Chello M; Covino E; Wolf FI; Minotti G
    Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2727-37. PubMed ID: 25596534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.